Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-05-30
2008-08-19
Allen, Marianne P. (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000
Reexamination Certificate
active
07413866
ABSTRACT:
The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 5994519 (1999-11-01), Osbourn et al.
patent: 6084075 (2000-07-01), Lind et al.
patent: 6140064 (2000-10-01), Loetscher et al.
patent: 6156520 (2000-12-01), Inglese et al.
patent: 6180336 (2001-01-01), Osbourn et al.
patent: 6184358 (2001-02-01), Loetscher et al.
patent: 6329159 (2001-12-01), Andrew et al.
patent: 6365356 (2002-04-01), Gershengorn
patent: 6448054 (2002-09-01), Poznansky et al.
patent: 6537764 (2003-03-01), Gerard et al.
patent: 6699677 (2004-03-01), Schall et al.
patent: 2002/0004215 (2002-01-01), Osbourn et al.
patent: 2002/0018776 (2002-02-01), Hancock
patent: 2002/0025536 (2002-02-01), Gyuris et al.
patent: 2002/0034757 (2002-03-01), Cubicciotti
patent: 2002/0037539 (2002-03-01), Qin et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061599 (2002-05-01), Elling et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0064770 (2002-05-01), Nestor, Jr. et al.
patent: 2002/0076710 (2002-06-01), Papsidero et al.
patent: 0897980 (1999-02-01), None
patent: WO 98/11218 (1998-03-01), None
patent: WO 98/14480 (1998-04-01), None
patent: WO 99/50461 (1999-10-01), None
Babcock, Gregory J. et al.; “Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes”;The Journal of Biological Chemistry2001, vol. 276 No. 42, pp. 38433-38440.
Baribaud, Frederic et al.; “Antigenically Distinct Conformations of CXCR4”;Journal of Virology2001, vol. 75 No. 19, pp. 8957-8967.
Dairaghi, Daniel J.; “HHV8-encoded vMIP-1 Selectively Engages Chemokine Receptor CCR8”;The Journal of Biological Chemistry1999, vol. 274, No. 31, pp. 21569-21574.
Dragic, Tatjana; “An overview of the determinants of CCR5 and CXCR4 co-reseptor function”;Journal of General Virology2001, vol. 82, pp. 1807-1814.
Forster, Reinhold et al.; “Intracellular and Surface Expression of the HIV-1 Coreceptor CXCR4/Fusin on Various Leukocyte Subsets: Rapid Internalization and Recycling Upon Activation”;The Journal of Immunology1998, vol. 160, pp. 1522-1531.
Gerlach, Lars Ole et al.; “Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor”;The Journal of Biological Chemistry2001, vol. 276 No. 17, pp. 14153-14160.
Gosling, Jennifa et al.: “Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK”;The Journal of Immunology2000, pp. 2851-2856.
Kledal, Thomas N. et al.; “A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus”;Science1997, vol. 277, pp. 1656-1659.
Lee, Benhur et al.; “Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function”;The Journal of Biological Chemistry1999, vol. 274 No. 14, pp. 9617-9626.
Moepps, Barbara et al.; “Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1α activation of G12are differently expressed in vivo”;Eur. J. Immunol.1997, vol. 27, pp. 2102-2112.
Muller, Anja et al.; “Involvement of chemokine receptors in breast cancer metastasis”;Nature2001, vol. 410, pp. 50-56.
Parolin, Cristina et al.; “Use of Murine CXCR-4 as a Second Receptor by Some T-Cell-Tropic Human Immunodeficiency Viruses”;Journal of Virology1998, vol. 72 No. 2, pp. 1652-1656.
Wegner, Scott A. et al.; “Genomic Organization and Functional Characterization of the Chemokine Receptor CXCR4, a Major Entry Co-receptor for Human Immunodeficiency Virus Type 1”; 1998The Journal of Biological Chemistry1998 vol. 273 No. 8, pp. 4754-4760.
Yoshida, Tetsuya et al.; “Identification of Single C Motif-1/Lymphotactin Receptor XCR1”;The Journal of Biological Chemistry1998, vol. 273 No. 26, pp. 16551-16554.
Abdel-Magid, Ahmed F. et al.; “Reductive Amination of Aldehydes and Ketones by Using Sodium Triacetoxyborohydride”;Tetrahedron Lett., 1990, vol. 31, pp. 5595-5598.
Barney, Charlotte L. et al.; “A Convenient Synthesis of Hindered Amines and α-Trifluoromethylamines from Ketones”;Tetrahedron Lett., 1990, vol. 31, pp. 5547-5550.
Bertolini, Francesco et al.; “Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma”;Blood, 2000, vol. 96, No. 1, pp. 282-287.
Bertolini, Francesco et al.; “CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin's Lymphoma”;Cancer Research, 2002, vol. 62, pp. 3106-3112.
Gribble, Gordon, W. et al.; “Reactions of Sodium Borohydride in Acidic Media; XVI. N-Methylation of Amines with Paraformaldehyde/Trifluoroacetic Acid”;Synthesis, 1987, pp. 709-711.
Kevill, Dennis N. et al.; “Correlation of the Rates of Solvolysis of Allyl and Benzyl Arenesulphonates”;Journal of Chemical Society Perkin Trans., 1984, vol. 2, pp. 717-720.
Lin, Engnian et al.; “Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2”;Proc. Natl. Acad. Sci.1998, vol. 95, pp. 8829-8834.
Liotta, Lance A.; “An attractive force in metastasis”;Nature, 2001, vol. 410, pp. 24-25.
Mattson, Ronald J. et al.: “An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride”;J. Org. Chem., 1990, vol. 55, pp. 2552-2554.
Muller, Anja et al.; “Involvement of chemokine receptors in breast cancer metastasis”;Nature, 2001, vol. 410, pp. 50-56.
Neises, Bernhard et al.; “Simple Method for the Esterification of Carboxylic Acids”;Angew. Chem. Int. Ed. Engl., 1978, vol. 17, No. 7, pp. 522-524.
Neote, Kuldeep, et al.; “Molecular Cloning, Functional Expression, and Signaling Characteristics of C-C Chemokine Receptor”;Cell, 1993, vol. 72, pp. 415-425.
Oppenheim, Joost J. et al.; “Properties of the Novel Proinflammatory Supergene “Intercrine” Cytokine Family”;Annu. Rev. Immunol., 1991, vol. 9, pp. 617-648.
Ponath, Paul D. et al.; “Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils”;J. Exp. Med., 1996, vol. 183, pp. 2437-2448.
Power, Christine A. et al.; “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Lines”;The Journal of Biological Chemistry, 1995, vol. 270, No. 33, pp. 19495-19500.
Pulaski, Beth A. et al.; “Cooperativity ofStaphylococcal aureusEnterotoxin B Superantigen, Major Histocompatibility Complex Class II, and CD80 for Immunotherapy of Advanced Spontaneous Metastases in a Clinically Relevant Postoperative Mouse Breast Cancer Model”:Cancer Research, 2000, vol. 60, pp. 2710-2715.
Schall, Thomas J.; “Biology of the Rantes/sis Cytokine Family”;Cytokine, 1996, vol. 3, No. 3, pp. 165-183.
Watanabe, Yoshihisa et al.; “The Selective Amination of Carbonyl Compounds using Iron Pentacarbonyl”;Tetrahedron Lett., 1974, vol. 22, pp. 1879-1880.
Ebert, Lisa M. et al.; “Core
Burns Jennifer M.
Howard Maureen C.
Miao Zhenhua
Premack Brett A.
Schall Thomas J.
Allen Marianne P.
ChemoCentryx, Inc.
DeBerry Regina M
Townsend and Townsend / and Crew LLP
LandOfFree
Compositions and methods for detecting and treating diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for detecting and treating diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for detecting and treating diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018714